Following the success of imatinib (Glivec) and trastuzumab (Herceptin), the search is on for more rational therapies. But what are the best targets, and how might they be modulated in cancer cells? Three articles explore these concepts in this issue.

The most advanced situation is discussed by Julian Downward on page 11. He describes the RAS pathway, which is activated in many human cancers in a variety of ways ? from amplification of the growth factor receptor ERBB2, to mutation of RAS itself ? so represents an excellent target for inhibition. Several therapeutic agents that target this pathway are showing promise as anticancer agents in the clinic.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD